Acquiring Company
Helus Pharma
Acquired Company
the CYB004-E Study
TorontoOtherManufacturingBiotechnologyHealth CarePharmaceuticalOtherConsumer GoodsScience And EngineeringGovernment And MilitaryDescription
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”) study (the “Acquisition”) from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”) to accelerate the clinical development path for CYB004, Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders.
Who to call at Helus Pharma, and when
When Helus Pharma changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Helus Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Helus Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Helus Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Helus Pharma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired the CYB004-E Study?
the CYB004-E Study was acquired by Helus Pharma, based in Toronto. The deal was reported on June 7, 2022. Helus Pharma is a mental health-focused biopharmaceutical company developing small-molecule Novel Serotonergic Agonists (NSAs) to improve treatment options. Helus Pharma is publicly traded (HELP) and operates in Other.
When did Helus Pharma acquire the CYB004-E Study?
Helus Pharma's acquisition of the CYB004-E Study was reported on June 7, 2022. Cybin Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does the CYB004-E Study do?
The CYB004-E study is an adaptive, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics (“PK”) and pharmacodynamics (“PD”) of a target-controlled intravenous infusion of DMT in healthy smokers. It is privately held, operating in Other.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.